Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC

Commentary
Podcast

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

This week, CancerNetwork® turns to the second episode in its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology at the Mayo Clinic in Phoenix, Arizona, led a discussion with Kristen Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and John Strickler, MD, associate professor of medicine and co-leader of the Molecular Tumor Board at Duke University School of Medicine in Durham, North Carolina.

This episode’s discussion turns to the GOZILA platform and its international collaborators. The experts expand on this platform and what it means for drug development as well as genetic testing in gastrointestinal malignancies.

Tune in next week for the third and final part of this conversation on colorectal cancer. Take a listen to the first episode of this series:

  • Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Related Content
FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

November 16th 2023
Article

First-line pembrolizumab plus chemotherapy has been approved by the FDA for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma

November 9th 2023
Article

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

CMG901 demonstrated a well-tolerated safety profile in patients with CLDN18.2-positive, advanced gastric/gastroesophageal junction cancer.

CMG901 Shows Potential in CLDN18.2-Positive Advanced Gastric/GEJ Cancer

November 8th 2023
Article

CMG901 demonstrated a well-tolerated safety profile in patients with CLDN18.2-positive, advanced gastric/gastroesophageal junction cancer.

Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.

Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers

November 7th 2023
Article

Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.